New Real-World Data from Medtronic Global SYMPLICITY Registry Show Renal Denervation Lowered Blood Pressure in Patients with Hypertension Out to Three Years

Rhea-AI Summary

Medtronic reports significant three-year outcomes from the Global SYMPLICITY Registry, demonstrating that renal denervation (RDN) with the Symplicity™ System leads to substantial and lasting reductions in blood pressure (BP) for hypertensive patients. Office systolic BP decreased by 17 mmHg, with two-thirds of patients initially over 180 mmHg achieving lower BP levels. These results, achieved while patients remained on an average of four anti-hypertensive medications, underscore RDN's efficacy and safety, with a renal artery stenosis incidence of only 0.3%.

Positive

• Significant reduction in office systolic blood pressure by 17 mmHg over three years.
• Two-thirds of patients with systolic BP >180 mmHg saw drops to lower risk levels.
• Increase in patients achieving controlled BP (<140 mmHg) from 13% to 39% at three years.
• Sustained results despite unchanged anti-hypertensive medication burden.
• Strong safety profile with 0.3% incidence of renal artery stenosis.

Negative

• None.

Regardless of the Number of Anti-Hypertensive Medications Prescribed, Majority of Patients with Highest BP Showed Significant Drops at Three Years

DUBLIN, June 25, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today reported new data from the Global SYMPLICITY Registry (GSR), which showed that renal denervation (RDN) with the Medtronic Symplicity™ Renal Denervation System significantly reduced blood pressure (BP) in uncontrolled hypertension patients out to three years independent of anti-hypertension medication burden. The data were presented virtually as part of the PCR e-Course 2020.

The study showed RDN led to significant and clinically meaningful reductions in blood pressure that were sustained out to three years post-procedure (17 mmHg OSBP (office systolic blood pressure)), with more patients achieving BP below 140 mmHg, while those at very high BP levels experiencing drops into lower risk BP ranges. The number of patients at the very highest BP level – greater than 180 mmHg systolic at baseline – dropped by two-thirds at three years. Additionally, the number of patients who had reported office systolic BP less than 140 mmHg – a more controlled level of BP – increased from 13 percent at baseline to 39 percent at three years. The BP drops occurred while patients were prescribed an average of four or more anti-hypertensive medications, which remained unchanged over three years. The absence of increase in medications suggest that RDN’s effect was independent of anti-hypertensive medication burden. RDN continued to show a strong safety profile at three years with an incidence of renal artery stenosis of 0.3 percent, which is within the expected range for patients with hypertension not undergoing denervation.

“In the largest real-world study of patients receiving renal denervation, we are seeing significant and clinically meaningful reductions in both office and 24-hr blood pressure sustained out to three years post-procedure, which demonstrates the durability of RDN,” said Felix Mahfoud, M.D., cardiologist at Saarland University Medical Center in Homburg, Germany, who presented the data during the meeting. “These data reinforce that RDN is a viable, complementary option with positive effects on hypertensive patients without requiring an increase in medication burden over time.”

The Global SYMPLICITY Registry is the largest study documenting the long-term safety and effectiveness of the Medtronic renal denervation systems in a real-world setting in patients with uncontrolled hypertension. To date, the registry has enrolled more than 2,860 patients treated with RDN and includes three-year follow-up for more than 2,500 patients. The data presented at PCR closely mirror a recent manuscript of GSR data published in JACC, which reported that RDN showed lasting results in a variety of high-risk patients, including those with diabetes, chronic kidney disease (CKD), isolated systolic hypertension (ISH), or resistant hypertension.

"Following the positive SPYRAL HTN-OFF MED Pivotal data presented at ACC, these new data provide additional evidence on the safety and efficacy of renal denervation to help manage uncontrolled hypertension, with study patients experiencing meaningful blood pressure reductions out to several years,” said Dave Moeller, vice president and general manager of the Coronary and Renal Denervation business, which is part of the Cardiac and Vascular Group at Medtronic. "As the body of clinical evidence supporting renal denervation grows, we are encouraged by the outcomes observed in both controlled clinical trials and real-world practice.”

Hypertension is the single largest contributor to cardiovascular death; it dramatically increases risk of heart attack, stroke, heart failure, and kidney failure. The annual direct costs of hypertension are estimated at $500 billion worldwide. It is estimated that almost 20 percent of patients are completely non-adherent to oral medications while nearly half are partially non-adherent, highlighting the need for alternative treatment options.

In addition to the Global SYMPLICITY Registry, the Medtronic SPYRAL HTN Global Clinical Program includes the SPYRAL HTN-OFF MED PIVOTAL and SPYRAL HTN-ON MED Trials, both prospectively powered, randomized, sham-controlled studies evaluating patients with uncontrolled blood pressure in the absence and presence of prescribed anti-hypertensive medications respectively. Approved for commercial use in more than 50 countries around the world, the Symplicity Spyral™ system is limited to investigational use in the United States.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Joey Lomicky
Public Relations
+1-763-381-1204

Ryan Weispfenning
Investor Relations
+1-763-505-4626

FAQ

What were the key findings from Medtronic's Global SYMPLICITY Registry for MDT?

The registry showed that renal denervation resulted in a 17 mmHg reduction in office systolic BP after three years, with significant improvements in hypertensive patients.

How does renal denervation impact patients on anti-hypertensive medication?

Patients experienced significant BP reductions while maintaining an average of four anti-hypertensive medications over three years, indicating RDN's independent efficacy.

What is the safety profile of Medtronic's renal denervation procedure?

The procedure showed a renal artery stenosis incidence of only 0.3%, well within expected ranges for hypertensive patients.

How many patients were involved in the Global SYMPLICITY Registry?

The registry has enrolled over 2,860 patients treated with renal denervation, with more than 2,500 having three-year follow-up.

When were the results of the Global SYMPLICITY Registry presented?

The data were presented virtually as part of the PCR e-Course 2020 on June 25, 2020.